Clinical TrialJun 1, 2026, 07:37 AM
Eikon Therapeutics Reports Strong EIK1001 & EIK1003 Clinical Data
AI Summary
Eikon Therapeutics announced updated clinical data for its lead programs, EIK1001 and EIK1003, presented at the 2026 ASCO Annual Meeting. The Phase 2 TeLuRide-005 trial for EIK1001 in NSCLC showed an overall objective response rate (ORR) of 63.1% and a disease control rate (DCR) of 90.8%, with a generally well-tolerated safety profile. The Phase 1/2 EIK1003 trial reported an ORR of 14.3% as monotherapy and 24.5% in combination with paclitaxel, demonstrating anti-tumor activity in advanced solid tumors.
Key Highlights
- EIK1001 Phase 2 NSCLC trial (TeLuRide-005) achieved 63.1% overall ORR and 90.8% DCR.
- EIK1001 non-squamous cohort showed 55.6% ORR and median duration of response over 11 months.
- EIK1001 squamous cohort demonstrated 72.4% ORR and 100% DCR.
- EIK1001 combination with standard of care was generally well-tolerated with manageable adverse events.
- EIK1003 Phase 1/2 monotherapy (Cohort 1A) achieved 14.3% ORR overall in advanced solid tumors.
- EIK1003 combination with paclitaxel (Cohort 1C) showed 24.5% ORR in advanced solid tumors.
- EIK1003 combination with paclitaxel had a safety profile consistent with paclitaxel's known toxicities.
- Eikon also presented First-in-Human study data for EIK1005 (WRN inhibitor).
Price Impact
More from EIKN